Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine
Autore:
Spina, E; Avenoso, A; Facciola, G; Scordo, MG; Ancione, M; Madia, A;
Indirizzi:
Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Policlin Univ, I-98125 Messina, Italy Univ Messina Messina Italy I-98125 Policlin Univ, I-98125 Messina, Italy Ctr Mental Hlth, Messina, Italy Ctr Mental Hlth Messina ItalyCtr Mental Hlth, Messina, Italy
Titolo Testata:
THERAPEUTIC DRUG MONITORING
fascicolo: 3, volume: 23, anno: 2001,
pagine: 223 - 227
SICI:
0163-4356(200106)23:3<223:PCORA9>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; HUMAN LIVER-MICROSOMES; CYTOCHROMES P450 2D6; IN-VITRO; PHARMACOKINETICS; METABOLISM; CLOZAPINE; SCHIZOPHRENIA; FLUVOXAMINE; SERTRALINE;
Keywords:
risperidone; 9-hydroxyrisperidone; paroxetine; drug interaction; CYP2D6;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Spina, E Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Policlin Univ, Torre Biol,5 Piano,Via Consolare Valeria, I-98125 Messina, Italy Univ Messina Torre Biol,5 Piano,Via Consolare Valeria Messina Italy I-98125
Citazione:
E. Spina et al., "Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine", THER DRUG M, 23(3), 2001, pp. 223-227

Abstract

The effects of paroxetine on steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) werestudied in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized using risperidone therapy (4-8 mg/d) also received paroxetine (20 mg/d) for 4 weeks. During paroxetine administration, mean plasma concentrations of risperidone increased significantly (P < 0.01), whereas levels of 9-OH-risperidone decreased slightly but not significantly. After 4 weeks of paroxetine treatment, the sum of the concentrations of risperidone and 9-OH-risperidone (active moiety) increased significantly by 45% (P < 0.05) over baseline. The mean plasma risperidone/9-OH-risperidone ratio was also significantly modified (P < 0.001) during paroxetine treatment. The drug combination was generally well tolerated with the exception of one patient who developed Parkinsonian symptoms in the second week of adjunctive therapy. In this patient total plasma levels of risperidone and its active metabolite increased by 62% during paroxetine co-administration. The authors' findings indicate that paroxetine, a potent inhibitor of CYP2D6, may impair the elimination of risperidone, primarily by inhibiting CYP2D6-mediated 9-hydroxylation and to a lesser extent by simultaneously affecting the furthermetabolism of 9-OH-risperidone or other pathways of risperidone biotransformation. Careful clinical observation and possibly monitoring of plasma risperidone levels may be useful whenever paroxetine is co-administered with risperidone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 06:05:00